J&J Inks $2.2B Settlement For Off-Label Marketing, Kickbacks

Law360, New York (November 04, 2013, 11:42 AM ET) -- Johnson & Johnson will admit to criminal misconduct and will shell out $2.2 billion to resolve whistleblowers' False Claims Act allegations it showered doctors with kickbacks and illegally promoted off-label uses of three drugs, including the antipsychotic medicine Risperdal, the U.S. Department of Justice said Monday.

The deal, which stems from at least four qui tam complaints, is one of the biggest in U.S. history involving health care fraud and was prompted in large part by marketing of Risperdal for unapproved indications, adding to New Jersey-based J&J's...
To view the full article, register now.